Clinical Trial Details

Trial ID: L0405
Source ID: IRCT20200531047614N2
Associated Drug: Melatonin
Title: The effects of melatonin supplementation compared with placebo on ultrasound findings and metabolic profiles in obese children and adolescents with nonalcoholic fatty liver disease
Acronym: --
Status: Recruiting
Study Results: No Results Available
Results: --
Conditions: Non alcoholic fatty liver disease (NAFLD). <br>Nonalcoholic steatohepatitis (NASH);K75.81
Interventions: Intervention 1: Intervention group: two melatonin tablets (Simorgh Darou Attar Co., Iran) 6 mg, 3 mg each tablet, once a day, one hour before bedtime for 16 weeks orally. Intervention 2: Control group: two Placebo tablets (Simorgh Darou Attar Co., Iran),
Outcome Measures: Hs-CRP. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Elisa kit.Severity of liver steatosis. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Sonography.;Serum liver enzymes. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;Total cholesterol. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Enzymatic kit.;Malondialdehyde. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 16 weeks of intervention. Method of measurement: Spectrophotometry.
Sponsor/Collaborators: Kashan University of Medical Sciences
Gender: All
Age: 10 years18 years
Phases: Phase 3
Enrollment: 66
Study Type: interventional
Study Designs: Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be randomly assigned into two groups. A randomization list will be generated from 1 to 66 by a random nu
Start Date: 13/11/2020
Completion Date: --
Results First Posted: --
Last Update Posted: 30 November 2020
Locations: Iran (Islamic Republic of)
URL: http://en.irct.ir/trial/51620